Glimepiride Metformin Pioglitazone 1mg 500mg 15mg Tablet

ZULIP-GP1 is an advanced triple combination anti-diabetic tablet manufactured and delivered by Arlak Corazone. It is designed to effectively control blood glucose levels in patients with Type 2 Diabetes Mellitus (T2DM). Formulated with Glimepiride, Metformin, and Pioglitazone, it targets multiple mechanisms of blood sugar regulation, offering better glycemic control and reducing insulin resistance.

Manufactured by Arlak Corazon, a trusted name in high-quality pharmaceutical formulations, ZULIP-GP1 is developed for patients who require combination therapy for effective diabetes management. It not only helps maintain fasting and postprandial glucose levels but also promotes overall metabolic balance and insulin sensitivity.

Mechanism of Action

ZULIP-GP1 combines three potent anti-diabetic agents with complementary actions:

• Glimepiride (1 mg): A sulfonylurea that stimulates the pancreas to release more insulin, thereby lowering blood sugar levels. It helps improve insulin secretion and enhances peripheral glucose uptake.
• Metformin (500 mg): A biguanide that reduces hepatic glucose production (gluconeogenesis), improves insulin sensitivity, and decreases glucose absorption from the intestines. It plays a central role in preventing hyperglycemia and improving lipid metabolism.
• Pioglitazone (15 mg): A thiazolidinedione (TZD) that increases insulin sensitivity in muscle and adipose tissue. It enhances the body’s response to insulin, promotes glucose utilization, and helps in reducing insulin resistance.

Indications for Use

ZULIP-GP1 is indicated for condition such as :

• Management of Type 2 Diabetes Mellitus (T2DM) in adults
• Patients inadequately controlled with monotherapy (Metformin or Sulfonylureas alone)
• Combination therapy for better control of fasting and postprandial blood sugar
• Patients requiring improved insulin sensitivity and reduced resistance

Dosage and Administration

The medication must be used as per doctor prescription . irregular use can cause serious risk:

• Usual recommended dose: One tablet daily, or as directed by a healthcare professional.
• To be taken with or after meals to minimize gastrointestinal side effects.
• Dose adjustments may be required depending on blood glucose monitoring and clinical response.
• Regular follow-up and lifestyle modification (diet and exercise) are advised alongside medication.

Possible Side Effects

Most side effects are mild and temporary and are tolerated by the body but in case it [resist consult your doctor. Commonly observed reactions include:

• Hypoglycemia (low blood sugar)
• Nausea, vomiting, or abdominal discomfort
• Weight gain or fluid retention (due to Pioglitazone)
• Headache or dizziness
• Mid gastrointestinal disturbances

Precautions

While using Zulip-GP1 we must follow few precaution in order to use it effectively and with a risk free treatment 

• Use with caution in patients with liver or kidney impairment.
• Not recommended in Type 1 diabetes or diabetic ketoacidosis.
• Monitor liver function and blood sugar levels regularly.
• Avoid alcohol as it may potentiate hypoglycemia.
• Pregnant or lactating women should use only under medical advice.
• Lifestyle measures such as a balanced diet, regular exercise, and weight control are essential for best results.

Storage Instructions 

• Keep the medication away from heat and wet/damp places , and store in a cool and dry place.
• Keep it away from direct sunlight
• Keep away from children 
• Must ensure the original packing is not broken before using or storing for a longer time.